Bremelanotide: First Approval

The FDA approval of bremelanotide (PT-141) in 2019 marked a historic milestone in the treatment of female sexual dysfunction. This publication by Dhillon and Keam documented the regulatory journey and clinical evidence that led to bremelanotide becoming the first on-demand treatment approved for hypoactive sexual desire disorder in premenopausal women.

The authors reviewed the comprehensive clinical development program for bremelanotide, including pivotal phase 3 trials that demonstrated its efficacy and safety. The review covered the peptide's pharmacology, clinical trial results, and the regulatory considerations that informed the FDA's approval decision.

The approval was supported by robust clinical evidence showing that bremelanotide effectively increases sexual desire and reduces distress related to low sexual desire in premenopausal women. Its unique on-demand dosing allows patients to use the therapy only when needed, offering flexibility not available with daily treatment alternatives.

This FDA approval represents a watershed moment for peptide-based therapies and women's sexual health. By establishing bremelanotide as a first-in-class approved treatment, this milestone validated the melanocortin receptor pathway as a viable therapeutic target and opened the door for broader acceptance of peptide therapies in mainstream clinical practice.